News Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (“Jaguar”) announced today that it has submitted three Investigational New Animal Drug Applications (“INADA”) with the Center for Veterinary Medicine of the US Food and Drug Administration (“CVM/FDA”) for SP-303 for use in dogs, cats and horses.

SP-303 is a drug candidate under development for watery diarrhea. SP-303 is isolated and purified from Croton lechleri, a plant sustainably harvested from the Amazon Basin under fair-trade work conditions. SP-303 is already the subject of a submission for MUMS designation for use in dogs with chemotherapy-induced diarrhea.

Jaguar’s Chief Veterinary Officer, Serge Martinod, DVM, Ph.D., commented, “Diarrhea is one of the most common reasons for dogs and cats go to the veterinarian and gastrointestinal problems, or at least their symptoms of vomiting and diarrhea are the most common cause of emergency room visits. Diarrhea in foals and in adult horses can be severe, many times leading to death if not treated, especially in stressed, highly valued competitive animals.”

Jaguar is also investigating products for cattle and other livestock. The latest figures from the USDA indicate that the annual number of beef and dairy calves born in the major cattle producing countries of the world was 34 million in the US; 29 million in Europe; 41.5 million in China; 51 million in Brazil; and 14 million in Argentina.

About Jaguar

Jaguar is focused on the development and commercialization of health solutions for the global veterinary marketplace from plants used traditionally in rain forest areas. Jaguar’s products will target companion animals, high valued racing animals, and livestock with both prescription pharmaceuticals and nutraceuticals.

Jaguar has an exclusive worldwide license from Napo Pharmaceuticals, Inc. (“Napo”) for all animal rights to products developed from Croton lechleri. In addition to the drug, SP-303, Jaguar is studying SB-300, a standardized botanical extract nutraceutical product derived from Croton lecheri in animals. Jaguar also has the exclusive worldwide veterinary license to Napo’s 2300 medicinal plant library and NP-500, a drug candidate under development to treat insulin resistant syndrome and Type II diabetes. Jaguar, pursuant to the license agreement, received certain manufacturing equipment and an inventory of products derived from Croton lechleri. Napo is a major shareholder of Jaguar.